Search
Corbus Pharmaceuticals Holdings Inc
CRBPAdd to Watchlist
9.250USD
+0.180+1.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
171.38MMarket Cap
LossP/E TTM
More Details of Corbus Pharmaceuticals Holdings Inc Company
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Corbus Pharmaceuticals Holdings Inc Info
Ticker SymbolCRBP
Company nameCorbus Pharmaceuticals Holdings Inc
IPO dateOct 24, 2014
CEOCohen (Yuval)
Number of employees28
Security typeOrdinary Share
Fiscal year-endOct 24
Address500 River Ridge Drive
CityNORWOOD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02062
Phone16179630103
Websitehttps://www.corbuspharma.com/
Ticker SymbolCRBP
IPO dateOct 24, 2014
CEOCohen (Yuval)
Company Executives of Corbus Pharmaceuticals Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
36.27K
-39.95%
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
27.90K
-40.01%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
16.02K
-94.61%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+61.18%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
6.58K
+57.72%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
6.58K
+57.72%
Dr. Ian Hodgson
Dr. Ian Hodgson
Chief Operating Officer
Chief Operating Officer
4.72K
-458.22%
Dr. Anne Altmeyer, Ph.D.
Dr. Anne Altmeyer, Ph.D.
Independent Director
Independent Director
2.78K
-86.79%
Dr. John Kenneth Jenkins, M.D.
Dr. John Kenneth Jenkins, M.D.
Independent Director
Independent Director
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
36.27K
-39.95%
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
27.90K
-40.01%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
16.02K
-94.61%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+61.18%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
6.58K
+57.72%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
6.58K
+57.72%
FAQs
Who are the top five shareholders of Corbus Pharmaceuticals Holdings Inc?
The top five shareholders of Corbus Pharmaceuticals Holdings Inc are: Dr. Yuval Cohen, Ph.D.
How many institutions hold shares of Corbus Pharmaceuticals Holdings Inc (CRBP)?
As of 2026Q1, 268 institutions hold shares of Corbus Pharmaceuticals Holdings Inc, with a combined market value of approximately 13.43M, accounting for 75.71% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2499912.00.